Showing 5461-5470 of 6036 results for "".
- 1-800 Contacts Enters Agreement to Acquire Vision Start-Up 6over6 Visionhttps://modernod.com/news/1-800-contacts-enters-agreement-to-acquire-vision-start-up-6over6-vision/2477177/1-800 Contacts announced that it entered into a definitive agreement to acquire 6over6 Vision (6over6), a provider of at-home vision tests using a mobile app or computer. Terms of the deal were not disclosed. 6over6 currently offers a vari
- FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)https://modernod.com/news/fda-advisory-committee-votes-unanimously-to-support-the-use-of-teprotumumab-for-the-treatment-of-thyroid-eye-disease-ted/2477171/Horizon Therapeutics announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the FDA voted unanimously that the potential benefits of teprotumumab, a fully human monoclonal antibody (mAb), outweigh the potential risks for the treatment of Thyroid Eye Disease (TED).
- Novartis Receives Positive CHMP Opinion for Beovu (Brolucizumab) for the Treatment of Wet AMDhttps://modernod.com/news/novartis-receives-positive-chmp-opinion-for-beovu-brolucizumab-for-the-treatment-of-wet-amd/2477172/Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Beovu (brolucizumab 6 mg), also known as RTH258, an investigational product for the treatment of wet age-related macular degeneration (AMD).<
- UK Regulator Unconditionally Clears Roche’s Purchase of Spark Therapeuticshttps://modernod.com/news/uk-regulator-unconditionally-clears-roches-purchase-of-spark-therapeutics/2477170/The UK Competition and Markets Authority (CMA) announced Monday the clearance of Roche’s proposed purchase of Spark Therapeutics after concluding that the deal would not negatively affect competition for haemophilia A treatments. The Swiss drugmaker noted that the offer period under the tra
- Horizon Therapeutics Trading Halted Today; FDA Committee Meeting to Discuss Teprotumumab for Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-trading-halted-today-fda-committee-meeting-to-discuss-teprotumumab-for-thyroid-eye-disease/2477167/Horizon Therapeutics announced that NASDAQ has halted trading of the company’s common stock, listed as HZNP. As per the FDA guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is holding a meeting today from 8 am to 4 pm ET to discuss
- GenSight Biologics Reports Findings From Studies Highlighting Benefits From Lumevoq Compared to LHON Natural Historyhttps://modernod.com/news/gensight-biologics-reports-findings-from-studies-highlighting-benefits-from-lumevoq-compared-to-lhon-natural-history/2477163/GenSight Biologics reported results from the REALITY registry study and an analysis of REVERSE and RESCUE phase 3 data, which further highlight the poor prognosis for patients with loss of vision due to Leber Hereditary Optic Neuropathy (LHON) associated with the ND4 mutation. The results
- Watching for Radiation Harm After Interventional Procedureshttps://modernod.com/news/watching-for-radiation-harm-after-interventional-procedures/2477165/Interventional procedures can expose interventionalists and nearby staff to high doses of radiation, and this can lead to radiation-associated lens opacities, said Madan Rehani, PhD, director of Global Outreach for Radiation Protection at Massachusetts General Hospital in Boston, in a Medscape
- Genentech/Roche’s Faricimab Phase 3 Program Fully Recruited with Enrollment Completion of Wet AMD Clinical Trialshttps://modernod.com/news/genentech-roches-faricimab-phase-3-program-fully-recruited-with-enrollment-completion-of-wet-amd-clinical-trials/2477161/Genentech and Roche have completed patient enrollment in the TENAYA and LUCERNE phase 3 clinical trials investigating faricimab for the treatment of wet age-related macular degeneration (AMD). The phase 3 YOSEMITE and RHINE diabetic macular edema (DME) clinical trials completed patient enrollment
- Bausch + Lomb Introduces Envista Toric MX60ET IOL With Stableflex Technologyhttps://modernod.com/news/bausch-lomb-introduces-envista-toric-mx60et-iol-with-stableflex-technology/2477160/Bausch + Lomb has introduced the enVista toric MX60ET hydrophobic acrylic IOL with StableFlex technology. Bausch + Lomb says the MX60ET provides improved material properties to deliver enhanced optic recovery following delivery. Like the enVista toric MX60T, the MX60ET offers a glistening free op
- Tom Frinzi to Retire; Warren Foust Appointed President of J&J Vision Surgicalhttps://modernod.com/news/tom-frinzi-to-retire-from-johnson-replaced-by-warren-foust/2477156/Johnson & Johnson Vision announced that Warren Foust will assume the role of Worldwide President, Surgical for Johnson & Johnson Vision, effective December 2. Mr. Foust replaces Tom Frinzi, who will retire at the end of 2019 after a 35-year career in ophthalmology. Mr. Frinzi was